Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | DUT | P33316 | 13/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20599908 | 0.86 | PKM (0.57) | PKML3MBTL1DUTCRBN | |
| SCHEMBL26916017 | 0.83 | L3MBTL1 (0.54) | PKML3MBTL1DUTCRBN | |
| SCHEMBL26915664 | 0.81 | L3MBTL1 (0.58) | PKML3MBTL1DUTCRBN | |
| SCHEMBL22193321 | 0.81 | L3MBTL1 (0.51) | PKML3MBTL1DUTCRBN | |
| SCHEMBL4348697 | 0.80 | L3MBTL1 (0.59) | PKML3MBTL1DUTCRBN | |
| SCHEMBL7131306 | 0.79 | PKM (0.53) | PKML3MBTL1DUTCRBN | |
| SCHEMBL31592762 | 0.77 | L3MBTL1 (0.58) | PKML3MBTL1DUTCRBN | |
| SCHEMBL4286089 | 0.77 | PKM (0.57) | PKML3MBTL1DUTCRBN | |
| SCHEMBL9694561 | 0.77 | PKM (0.54) | PKML3MBTL1DUTCRBN | |
| SCHEMBL16327292 | 0.75 | DUT (0.55) | PKMDUTCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371395-A1 | URACIL COMPOUND AS C-MET/AXL INHIBITOR | MEDSHINE DISCOVERY, INC. (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371395-A1 | URACIL COMPOUND AS C-MET/AXL INHIBITOR | AXL, MET, FLT3 | PKM 2669/4885L3MBTL1 2104/4885DUT 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.